What are the key commercialization rights BeOne has secured?

BeOne has secured the rights to commercialize Amgen's oncology products XGEVA®, KYPROLIS®, and BLINCYTO® in China. Additionally, BeOne will have the right to commercialize certain approved pipeline products globally in China after their development.

What is the financial impact of Amgen's equity stake?

Amgen is acquiring a 20.5% equity stake in BeOne for approximately $2.7 billion. This investment was made at a 36% premium to BeOne's 30-day average ADS trading price, providing BeOne with significant capital and validating the company's market position.

How will BeOne benefit from the pipeline product collaboration?

BeOne will co-develop 20 Amgen pipeline oncology products globally, with primary development activities in China. BeOne will co-fund these development costs and is eligible to receive tiered royalties on global net sales outside of China. Furthermore, BeOne has the right to commercialize certain approved pipeline products in China and retain them for the duration of their sales.

What are the conditions for the closing of these transactions?

The transactions are contingent upon several conditions, including approval by a majority vote of BeOne's shareholders, expiration or termination of applicable antitrust waiting periods, satisfaction of other customary closing conditions, and the effectiveness of the collaboration and share purchase agreements.

ONC 8-K: Material Agreements & Securities & Listing

Summary

BeOne Medicines Ltd. (ONC) announced a significant strategic collaboration with Amgen Inc. on October 31, 2019. This partnership involves Amgen granting BeOne exclusive rights to commercialize three of Amgen's key oncology products – XGEVA®, KYPROLIS®, and BLINCYTO® – within China. Furthermore, BeOne will co-develop and co-commercialize 20 Amgen pipeline oncology products globally, with a primary focus on development activities within China. This collaboration is strengthened by a substantial equity investment from Amgen, which will acquire a 20.5% stake in BeOne for approximately $2.7 billion at a significant premium. The financial implications for BeOne are substantial, with the equity investment providing a significant capital infusion. The collaboration structure allows BeOne to share equally in profits and losses for the commercialized products in China and potentially retain certain pipeline products for exclusive commercialization. BeOne is also committed to co-funding global development costs, contributing up to $1.25 billion in development services and cash. These transactions are subject to shareholder approval and regulatory clearances, with an expected closing in the first quarter of 2020.

Key Highlights

1Amgen and BeOne enter a strategic collaboration focused on oncology products.
2BeOne gains exclusive China commercialization rights for Amgen's XGEVA®, KYPROLIS®, and BLINCYTO®.
3Global development and commercialization rights for 20 Amgen pipeline oncology products are shared.
4Amgen invests approximately $2.7 billion for a 20.5% equity stake in BeOne at a 36% premium.
5BeOne will contribute up to $1.25 billion towards global development of Amgen's pipeline products.
6The deal includes profit and loss sharing for commercialized products in China.
7Transactions are subject to shareholder approval and regulatory conditions, with an expected Q1 2020 closing.

BeOne Medicines Ltd. 8-K Report, Material Agreement (Oct 31, 2019)

Summary

Key Highlights

Frequently Asked Questions